Details for Patent: 7,541,347

Which drugs does patent 7,541,347 protect, and when does it expire?

Patent 7,541,347 protects XIMINO and SOLODYN and is included in two NDAs.

This patent has twelve patent family members in nine countries.

Summary for Patent: 7,541,347

Title:	Minocycline oral dosage forms for the treatment of acne
Abstract:	Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Inventor(s):	Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
Assignee:	Medicis Pharmaceutical Corp
Application Number:	US11/695,528
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,541,347
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 7,541,347

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-001	Jul 11, 2012		DISCN	No	No						TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-003	Jul 11, 2012		DISCN	No	No						TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-005	Jul 11, 2012		DISCN	No	No						TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-002	May 8, 2006		DISCN	Yes	No						TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

International Family Members for US Patent 7,541,347

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006262428
Canada	2613273
China	101208097
European Patent Office	1898925
Japan	2008543936
Japan	2013213047